CHILDREN'S MOTRIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHILDREN'S MOTRIN (CHILDREN'S MOTRIN).
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
| Metabolism | Primarily hepatic via CYP2C9 (major) and CYP2C8 (minor) to inactive metabolites (e.g., hydroxylation, conjugation). |
| Excretion | Renal (90%) as inactive metabolites and conjugates; fecal (<5%). |
| Half-life | 2-4 hours in children; prolonged in neonates and hepatic impairment. |
| Protein binding | 99% primarily to albumin. |
| Volume of Distribution | 0.1-0.2 L/kg; low Vd indicates extensive plasma protein binding. |
| Bioavailability | Oral: 80-100%; well absorbed from GI tract. |
| Onset of Action | Oral: 30-60 minutes; peak effect at 1-2 hours. |
| Duration of Action | 4-6 hours; antipyretic effect may last up to 8 hours. |
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | GFR 30-60 mL/min: reduce dose by 25-50% or use alternate NSAID; GFR <30 mL/min: contraindicated or avoid use. |
| Liver impairment | Child-Pugh A: no adjustment needed; Child-Pugh B: reduce dose by 50% or use with caution; Child-Pugh C: contraindicated or avoid use. |
| Pediatric use | For fever or pain: 5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day or 1200 mg/day (whichever is less). For children aged 6 months to 12 years, weight-based dosing: 0.5-1 mL/kg of 100 mg/5 mL suspension per dose (or equivalent). |
| Geriatric use | Initiate at lowest effective dose (e.g., 200 mg every 8 hours); maximum 1200 mg/day; monitor renal function, GI bleeding risk, and drug interactions (e.g., anticoagulants, aspirin). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CHILDREN'S MOTRIN (CHILDREN'S MOTRIN).
| Breastfeeding | Ibuprofen is excreted in breast milk in very low amounts (M/P ratio approximately 0.5-1.0). The estimated infant daily dose is <1% of the maternal weight-adjusted dose. Considered compatible with breastfeeding by the AAP, but monitor infant for potential adverse effects such as gastrointestinal disturbance or thrombocytopenia. |
| Teratogenic Risk | First trimester: Observational studies suggest a small increased risk of cardiac defects and gastroschisis; avoid use if possible. Second trimester: No clear evidence of major teratogenicity, but use only if clearly needed. Third trimester: Not recommended due to risk of premature closure of the ductus arteriosus, oligohydramnios, and fetal nephrotoxicity. Use after 30 weeks is contraindicated. |
■ FDA Black Box Warning
Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, especially with prolonged use or in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft (CABG) surgery.
| Serious Effects |
Hypersensitivity to ibuprofen or any NSAID, history of asthma/urticaria after aspirin/NSAIDs, active GI bleeding or perforation, severe heart failure, perioperative pain in CABG surgery.
| Precautions | GI adverse events (bleeding, ulceration, perforation), renal toxicity (including papillary necrosis), serious skin reactions (e.g., Stevens-Johnson syndrome), anaphylactoid reactions, avoid in late pregnancy, may mask signs of infection. |
| Food/Dietary | No significant food interactions. Alcohol should be avoided due to increased risk of GI bleeding. May be taken with food or milk to minimize GI upset. |
Loading safety data…
| Fetal Monitoring | Monitor maternal renal function, blood pressure, and signs of bleeding. For third-trimester use, fetal ultrasound to assess ductus arteriosus patency and amniotic fluid volume. Observe newborn for signs of premature ductus closure, necrotizing enterocolitis, or intracranial hemorrhage if exposed near term. |
| Fertility Effects | Ibuprofen may reversibly impair female fertility by inhibiting prostaglandin synthesis, affecting ovulation and implantation. Discontinuation typically restores normal fertility. No known effect on male fertility in humans. |
| Clinical Pearls | Children's Motrin (ibuprofen) is an NSAID used for fever and pain. In pediatric patients, dosing is weight-based (5-10 mg/kg/dose every 6-8 hours, max 40 mg/kg/day). Do not exceed 4 doses per day. Avoid use in children with dehydration, renal impairment, or bleeding disorders. Onset of antipyresis typically within 30-60 minutes. Administer with food to reduce GI upset. Contraindicated in patients with aspirin allergy or active GI bleeding. Do not combine with other NSAIDs or anticoagulants. Monitor for signs of GI toxicity or renal impairment in prolonged use. |
| Patient Advice | Use the dosing device provided; do not use kitchen spoons. · Do not give more than 4 doses in 24 hours. · Shake well before each use. · Store at room temperature, away from heat and moisture. · Do not give with other products containing ibuprofen or other NSAIDs. · If fever persists >3 days or pain >10 days, consult a doctor. · Give with food or milk to prevent stomach upset. · Keep out of reach of children. · In case of overdose, seek medical attention immediately. |